Med Tech-related technology assessments from NICE in June 2025

The National Institute for Health and Care Excellence (NICE) develops Interventional Procedures Guidance (IPG) for most novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In June 2025, NICE published three new IPGs and made the following conclusions:

• Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation can be used in the NHS, while more evidence is generated when surgical aortic valve replacement (SAVR) is not suitable or is high risk. It can only be used with special arrangements for clinical governance, consent, and audit or research. In cases when SAVR is suitable and is not high risk, TAVI should be done only as part of a formal research study. NICE concluded that more research is needed on patient selection, comparisons between TAVI and SAVR or medical treatment, comparisons between different TAVI prosthetic aortic valves, long-term outcomes, and safety outcomes.
• Targeted muscle reinnervation for managing limb amputation pain can be used in the NHS with special arrangements for clinical governance, consent, and audit or research, while more evidence is generated, as a secondary procedure to treat problematic pain that has developed after limb amputation. Targeted muscle reinnervation as a primary procedure to prevent problematic pain from developing after limb amputation is recommended only as a part of a formal research study approved by the NHS Research Ethics Committee. More research is needed on patient selection, details of the technique used, the need for reintervention, short- and long-term outcomes, including effects on pain and quality of life.
• Laparoscopic insertion of an inactive implant for gastroesophageal reflux disease (GERD) can be used to treat GERD in people with ineffective esophageal motility (IOM), with special arrangements for clinical governance, consent, and audit or research while more evidence is generated. However, more research is needed on the procedure in people without IOM before it can be used in the NHS.

Furthermore, in June 2025, NICE updated three clinical guidelines on Intrapartum care, Caesarean birth, and Headaches in over 12s: diagnosis and management.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.